Last reviewed 2026-05-22 · How we verify

Propinox (PARGEVERINE)

Phase 2 active Small molecule ✓ Verified May 2026

Propinox (generic name: PARGEVERINE) is a pargeverine drug. It is currently in Phase 2 development.

Propinox works by interacting with a specific target in the body to produce a therapeutic effect.

Propinox is a small molecule. It is also known by the synonyms PARGEVERIN, PARGEVERINA, PARGEVERINE, and VIADIL.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PARGEVERINE
Drug class	pargeverine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have a specific lock on the surface, and Propinox is a key that fits into that lock. When it binds, it triggers a series of events that ultimately lead to the desired outcome. This process is complex and not fully understood, but it's the basis for how Propinox is thought to work.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Propinox CI brief — competitive landscape report
Propinox updates RSS · CI watch RSS

Frequently asked questions about Propinox

What is Propinox?

Propinox (PARGEVERINE) is a pargeverine drug.

How does Propinox work?

Propinox works by interacting with a specific target in the body to produce a therapeutic effect.

What is the generic name of Propinox?

PARGEVERINE is the generic (nonproprietary) name of Propinox.

What drug class is Propinox in?

Propinox belongs to the pargeverine class. See all pargeverine drugs at /class/pargeverine.

What development phase is Propinox in?

Propinox is in Phase 2.

Drug class: All pargeverine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing